ctDNA Status Predicts DFS Benefit of Celecoxib in Stage III Colon Cancer
Subgroup analysis of the CALGB/SWOG 80702 trial investigated the impact of ctDNA status on DFS in stage III resected colon cancer patients treated with celecoxib or placebo.
CRT Plus Chemo Did Not Improve RFS in Resected Gallbladder Cancer
Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.
Baseline Geriatric and QOL Factors Linked to Chemotherapy Survival in PDAC
The phase 2 EA2186 trial was the first elderly-specific clinical trial evaluating chemotherapy in vulnerable adults with metastatic pancreatic cancer.
Pamrevlumab Combo Does Not Improve Survival in Advanced Pancreatic Cancer
Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.
Nivolumab/Ipilimumab Yielded Superior Efficacy and Safety Data in uHCC
Nivolumab plus ipilimumab generated an ORR of 36% vs 13% from levantinib plus sorafenib in unresectable hepatocellular carcinoma in the CheckMate 9DW study.
Later-Line Surufatinib Combo Shows Promising Activity in Metastatic PDAC
Updated phase 2 results support further investigation of surufatinib plus TAS-012 in a larger cohort of patients with pancreatic ductal adenocarcinoma.
Patients With Extrapancreatic NETs Experience Improved PFS from Cabozantinib
Patients who received cabozantinib experienced a PFS of 8.5 months vs 5.6 months with placebo, a subgroup analysis from the CABINET trial found.
TACE Plus Camrelizumab/Rivoceranib Extends PFS in Unresectable Liver Cancer
Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.
Sintilimab Plus CRT Yields Superior Responses in Resectable, Locally Advanced ESCC
Sintilimab plus neoadjuvant chemoradiotherapy yielded a pCR rate of 60% vs 13% from sintilimab plus chemotherapy in patients with locally advanced ESCC.
FDA Approves Everolimus Extended-Release Capsules in TSC-Associated SEGA
2mg, 3mg, and 5mg extended-release capsules of everolimus have been approved for patients with TSC-associated SEGA by the FDA.
Neoadjuvant Pembrolizumab Appears Tolerable in Stage IIIB-D Melanoma
The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Tislelizumab/Chemo Demonstrates Promising Activity in Gastric/GEJ Cancer
Phase 1/2 SYLT-023 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in patients with advanced, HER2-negative, mismatch repair–proficient gastric/GEJ cancer.
Response Depth in High-Risk Smoldering Multiple Myeloma May Predict Outcomes
Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.
Trastuzumab Combo Shows Nonsignificant Advantages in Gastric/GEJ Cancer
Adding trastuzumab and pertuzumab to chemotherapy conferred higher toxicity among patients with HER2-positive gastric cancers in the INNOVATION trial.
Extended Analysis Finds Sustained Efficacy of Nivolumab Combo in GI Subtype
Results from the CheckMate 649 trial showed continued efficacy at 5 years in the nivolumab combination for patients with gastric/GEJ/esophageal cancer.
Nivolumab/Chemo Yields Improved Survival in Gastrointestinal Cancers
The CheckMate 649 trial found that nivolumab plus chemotherapy lead to a median OS of 14.3 months vs 10.3 months for chemotherapy alone in several gastrointestinal cancers.
FDA Puts Clinical Hold on Tabelecleucel in EBV+ PTLD, ATA3219 in Lymphoma
Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.
Evorpacept Elicits Favorable Responses in HER2+ Gastric/GEJ Cancer
Phase 2 results show clinical responses and survival benefits in patients with confirmed HER2-positive expression in gastric/gastroesophageal cancer.
Novel Combo Suppressed Chemo-Associated Myelosuppression in Gastric/GEJ Cancer
SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.
Camrelizumab Plus Chemo Yields Improved Response Rates in Gastric/GEJ Cancer
Results from the phase 2 FDZL-001 trial showed high OS and PFS rates when camrelizumab plus Nab-POF was used to treat patients with gastric/GEJ cancer.
ZL-1310 Receives Orphan Drug Designation in Small Cell Lung Cancer
A phase 1a/1b trial showed that ZL-1310 elicited an ORR of 74%, all of which were PRs, in patients with SCLC who received prior chemotherapy.
Galinpepimut-S Completes Phase 3 REGAL Interim Analysis in AML
Interim phase 3 results revealed a median survival of at least 13.5 months with galinpepimut-S vs 6 months with standard of care in acute myeloid leukemia.
Fulvestrant Yields No OS Differences Vs Anastrozole in HR+ Breast Cancer
Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.
Trastuzumab Combo Appears Effective, Tolerable in RAS/BRAF+ HER2+ CRC
Trastuzumab/pertuzumab elicited similar efficacy and fewer high-grade AEs vs cetuximab/irinotecan in RAS/BRAF wild-type, HER2–positive metastatic CRC.
Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC
A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.
Cancer Incidence Continues to Rise, Especially in Women Younger Than 65
Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.
Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM
Patients who received the isatuximab combination in the IMROZ trial experienced prolonged MRD-negativity, which correlated with improved PFS.
Artificial Intelligence May Expedite Prognoses in Cancer Care
In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
Enhanced Dermatologic Care Reduced AEs from MARIPOSA Regimen in NSCLC
Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.